Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal

Stock Markets Jun 03, 2022 10:43AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: A woman holds test tube in front of displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo 2/2
 
PFE
-1.04%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BMY
-0.74%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TPTX
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Manas Mishra and Amruta Khandekar

(Reuters) -Bristol Myers Squibb Co said on Friday it will acquire drug developer Turning Point Therapeutics (NASDAQ:TPTX) Inc for $4.1 billion in cash to help bolster its arsenal of cancer drugs.

Turning Point's lead drug, repotrectinib, targets mutations in certain proteins in the body that lead to unchecked cell growth.

Bristol Myers (NYSE:BMY) will pay $76 per Turning Point share, a 122.5% premium to its last closing price.

The deal comes at a time when a dearth of large acquisitions, clinical failures and investor exits following a gradual easing of the pandemic have hammered biotech stocks.

Wall Street analysts said the deal could help lift sector sentiment.

The deal "will surprise many investors who over the past year have begun to believe late-to-market targeted oncology drugs are likely to be commercial failures," Stifel analyst Bradley Canino said.

Turning Point's shares, which have fallen roughly 28% this year, more than doubled to $73.60 in early trading.

Repotrectinib belongs to a class of treatments known as tyrosine kinase inhibitors, and is being tested to treat non-small cell lung cancer (NSCLC) and other advanced solid tumors.

However, the drug, if approved, will compete in a crowded market for lung cancer treatments and contend for market share with Bristol Myers' own drug Opdivo, and other cancer drugs made by Roche, Merck & Co Inc and AstraZeneca (NASDAQ:AZN).

Bristol Myers said it expects repotrectinib to become a standard-of-care therapy for certain patients with NSCLC, a lucrative market for drug developers, when it is approved.

Sales of Bristol Myers' Opdivo have fallen below those of rival Merck's blockbuster treatment, Keytruda.

Bristol Myers expects U.S. approval for repotrectinib in the second half of 2023.

Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email